CCM
GILD icon

Cullen Capital Management’s Gilead Sciences GILD Stock Holding History

Cullen Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,815
Closed -$309K – 140
2017
Q3 		$309K Sell
3,815
-4,185
-52% -$320K 0.01% 125
2017
Q2 		$566K Buy
+8,000
New +$532K 0.02% 128

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cullen Capital Management's GILD Position: Q4 2017 in Review

Cullen Capital Management sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 3,815 shares — an estimated $309K sold.

Cullen Capital Management first reported a position in GILD in Q2 2017 and held it in 2 quarters. The position peaked at $566K in Q2 2017. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • Cullen Capital Management reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • Cullen Capital Management sold 3,815 Gilead Sciences shares in Q4 2017, an estimated $309K.
  • Cullen Capital Management first reported a position in Gilead Sciences in Q2 2017 and held it in 2 quarters.
  • Cullen Capital Management's Gilead Sciences position peaked at $566K in Q2 2017.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Cullen Capital Management's 13F filing for Q4 2017, filed 15 Feb 2018.